• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载阿昔洛韦固体脂质纳米粒的处方工艺研究:设计、优化与评价。

Formulation of acyclovir-loaded solid lipid nanoparticles: design, optimization, and characterization.

机构信息

Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University , Tanta , Egypt.

出版信息

Pharm Dev Technol. 2019 Dec;24(10):1287-1298. doi: 10.1080/10837450.2019.1667385. Epub 2019 Sep 26.

DOI:10.1080/10837450.2019.1667385
PMID:31507232
Abstract

The goal of this study was to design, optimize, and characterize Acyclovir-loaded solid lipid nanoparticles (ACV-SLNs) concerning particle size, zeta potential, entrapment efficiency, and release profile. Full factorial design (2) was applied and the independent variables were surfactant type (Tween 80 and Pluronic F68), lipid type (Stearic acid and Compritol 888 ATO), and co-surfactant type (Lecithin and Sodium deoxycholate). The microemulsion technique was used followed by ultrasonication. The ACV-SLNs had a particle size range of about 172-542 nm. The polydispersity index (PDI) was found to be between 0.193 and 0.526. Zeta potential was in the range of -25.7 to -41.6 mV indicating good physical stability. Entrapment efficiency values were in the range of 56.3-80.7%. The drug release kinetics of the prepared formulations was best fitted to Higuchi diffusion model. After storing ACV-SLNs at refrigerated condition (5 ± 3 °C) and room temperature (25 ± 2 °C) for 4 weeks; we studied the change in the particle size, PDI, and zeta potential. The selected optimized formulation (F4) was containing Compritol, Pluronic F68, and Lecithin. These results indicated the successful application of this design to optimize the ACV-SLNs as a promising delivery system.

摘要

本研究旨在设计、优化并表征载阿昔洛韦固体脂质纳米粒(ACV-SLNs),考察其粒径、Zeta 电位、包封率和释放特性。采用全因子设计(2),考察表面活性剂种类(吐温 80 和泊洛沙姆 F68)、脂质种类(硬脂酸和 Compritol 888 ATO)和助表面活性剂种类(卵磷脂和脱氧胆酸钠)这 3 个自变量。采用微乳法,随后进行超声处理。ACV-SLNs 的粒径范围约为 172-542nm。多分散指数(PDI)在 0.193-0.526 之间。Zeta 电位在-25.7 到-41.6mV 之间,表明具有良好的物理稳定性。包封率在 56.3-80.7%之间。所制备的制剂的药物释放动力学最符合 Higuchi 扩散模型。在冷藏(5±3°C)和室温(25±2°C)条件下储存 ACV-SLNs 4 周后,研究了粒径、PDI 和 Zeta 电位的变化。选择优化后的配方(F4),其包含 Compritol、泊洛沙姆 F68 和卵磷脂。这些结果表明成功应用该设计优化了 ACV-SLNs,使其成为一种有前途的给药系统。

相似文献

1
Formulation of acyclovir-loaded solid lipid nanoparticles: design, optimization, and characterization.载阿昔洛韦固体脂质纳米粒的处方工艺研究:设计、优化与评价。
Pharm Dev Technol. 2019 Dec;24(10):1287-1298. doi: 10.1080/10837450.2019.1667385. Epub 2019 Sep 26.
2
Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study.载阿昔洛韦固体脂质纳米粒的制剂研究:2. 脑靶向及药代动力学研究。
Pharm Dev Technol. 2019 Dec;24(10):1299-1307. doi: 10.1080/10837450.2019.1667386. Epub 2019 Sep 20.
3
Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.设计、表征和体内评价纳米结构脂质载体(NLC)作为氢氯噻嗪口服给药的新型药物传递系统在儿科治疗中的应用。
Drug Deliv. 2018 Nov;25(1):1910-1921. doi: 10.1080/10717544.2018.1529209.
4
Acyclovir Solid Lipid Nanoparticles for Skin Drug Delivery: Fabrication, Characterization and In vitro Study.用于皮肤给药的阿昔洛韦固体脂质纳米粒:制备、表征及体外研究
Recent Pat Drug Deliv Formul. 2017;11(2):132-146. doi: 10.2174/1872211311666170117123403.
5
Central Composite Design for Formulation and Optimization of Solid Lipid Nanoparticles to Enhance Oral Bioavailability of Acyclovir.中心复合设计用于制备和优化固体脂质纳米粒以提高阿昔洛韦的口服生物利用度。
Molecules. 2021 Sep 7;26(18):5432. doi: 10.3390/molecules26185432.
6
Impact of Pluronic F-68 vs Tween 80 on Fabrication and Evaluation of Acyclovir SLNs for Skin Delivery.普朗尼克F-68与吐温80对用于皮肤给药的阿昔洛韦固体脂质纳米粒制备及评价的影响
Recent Pat Drug Deliv Formul. 2016;10(3):207-221. doi: 10.2174/1872211310666160724213722.
7
Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.利福平载固体脂质纳米粒的制备、优化及表征及其在结核病治疗中的应用。
Drug Dev Ind Pharm. 2018 Dec;44(12):1975-1989. doi: 10.1080/03639045.2018.1506472. Epub 2018 Aug 31.
8
Benzocaine loaded solid lipid nanoparticles: Formulation design, in vitro and in vivo evaluation of local anesthetic effect.负载苯佐卡因的固体脂质纳米粒:制剂设计、局部麻醉作用的体外和体内评价
Curr Drug Deliv. 2015;12(6):680-92. doi: 10.2174/1567201812666150703115126.
9
Preparation, optimization, and characterization of α-tocopherol-loaded solid lipid nanoparticles (SLNs).α-生育酚负载固体脂质纳米粒(SLNs)的制备、优化与表征。
Drug Dev Ind Pharm. 2020 Jan;46(1):159-171. doi: 10.1080/03639045.2019.1711388. Epub 2020 Jan 13.
10
Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology.使用响应面法制备和优化阿托伐他汀负载固体脂质纳米粒的系统方法。
Biomed Microdevices. 2018 Jun 26;20(3):53. doi: 10.1007/s10544-018-0285-5.

引用本文的文献

1
A Comparative Mathematical Analysis of Drug Release from Lipid-Based Nanoparticles.脂质纳米粒药物释放的比较数学分析。
AAPS PharmSciTech. 2024 Sep 5;25(7):208. doi: 10.1208/s12249-024-02922-7.
2
mucilage nanoparticles of losartan potassium: Characterization and pharmacodynamics evaluation.氯沙坦钾黏液纳米颗粒:表征与药效学评价
Saudi Pharm J. 2023 Aug;31(8):101695. doi: 10.1016/j.jsps.2023.101695. Epub 2023 Jul 6.
3
Telmisartan-Loaded Lactosylated Chitosan Nanoparticles as a Liver Specific Delivery System: Synthesis, Optimization and Targeting Efficiency.
载替米沙坦乳糖化壳聚糖纳米粒作为肝靶向给药系统的研究:合成、优化及靶向效率。
AAPS PharmSciTech. 2023 Jun 23;24(6):144. doi: 10.1208/s12249-023-02605-9.
4
Folic Acid Functionalized Diallyl Trisulfide-Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer.叶酸功能化二烯丙基三硫代-固体脂质纳米粒用于靶向三阴性乳腺癌。
Molecules. 2023 Feb 1;28(3):1393. doi: 10.3390/molecules28031393.
5
Development and Optimization of Tamarind Gum-β-Cyclodextrin-g-Poly(Methacrylate) pH-Responsive Hydrogels for Sustained Delivery of Acyclovir.用于阿昔洛韦持续递送的罗望子胶-β-环糊精-g-聚(甲基丙烯酸酯)pH响应水凝胶的开发与优化
Pharmaceuticals (Basel). 2022 Dec 8;15(12):1527. doi: 10.3390/ph15121527.
6
Using pyrene to probe the effects of poloxamer stabilisers on internal lipid microenvironments in solid lipid nanoparticles.使用芘来探究泊洛沙姆稳定剂对固体脂质纳米粒内部脂质微环境的影响。
Nanoscale Adv. 2020 Oct 19;2(12):5572-5577. doi: 10.1039/d0na00582g. eCollection 2020 Dec 15.
7
Tetrahydrocurcumin Lipid Nanoparticle Based Gel Promotes Penetration into Deeper Skin Layers and Alleviates Atopic Dermatitis in 2,4-Dinitrochlorobenzene (DNCB) Mouse Model.基于四氢姜黄素脂质纳米粒的凝胶促进透皮进入更深层皮肤并减轻2,4-二硝基氯苯(DNCB)小鼠模型中的特应性皮炎
Nanomaterials (Basel). 2022 Feb 14;12(4):636. doi: 10.3390/nano12040636.
8
An Industrial Procedure for Pharmacodynamic Improvement of Metformin HCl via Granulation with Its Paracellular Pathway Enhancer Using Factorial Experimental Design.采用因子实验设计,通过颗粒化并用其细胞旁途径增强剂来提高盐酸二甲双胍药效学的工业方法。
Drug Des Devel Ther. 2021 Nov 2;15:4469-4487. doi: 10.2147/DDDT.S328262. eCollection 2021.
9
Use of nanotechnology in combating coronavirus.纳米技术在对抗冠状病毒中的应用。
3 Biotech. 2021 Jul;11(7):358. doi: 10.1007/s13205-021-02905-6. Epub 2021 Jun 28.
10
Advanced Material Against Human (Including Covid-19) and Plant Viruses: Nanoparticles As a Feasible Strategy.对抗人类(包括新冠病毒)和植物病毒的先进材料:纳米颗粒作为一种可行策略
Glob Chall. 2020 Dec 28;5(3):2000049. doi: 10.1002/gch2.202000049. eCollection 2021 Mar.